DB-1317 / DualityBio - LARVOL DELTA

DB-1317, a novel ADAM9-targeting antibody-drug conjugate, exhibits potent antitumor activity against multiple gastrointestinal cancers (AACR-NCI-EORTC 2025) - "DB-1317 demonstrated promising antitumor activities across various gastrointestinal cancers, with favorable PK and safety profiles."

Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • ADAM9

DB-1317-101: A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=233 | Recruiting | Sponsor: DualityBio Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Colorectal Cancer • Oncology • Solid Tumor

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=183 | Not yet recruiting | Sponsor: DualityBio Inc.

New P1 trial • Colorectal Cancer • Oncology • Solid Tumor